氟维司群治疗受体阳性晚期乳腺癌的疗效观察  

Therapeutic effect of fulvestrant on estrogen receptor–positive advanced breast cancer

作　　者：杨俊兰[1] 游俊浩[1] 韩春[1] 令狐锐霞[1] 朱艳云[1] 方平[1] 

机构地区：[1]解放军总医院肿瘤内科,北京100853

出　　处：《解放军医学院学报》2013年第4期327-328,共2页Academic Journal of Chinese PLA Medical School

摘　　要：目的总结氟维司群治疗受体阳性晚期乳腺癌的临床疗效及不良反应。方法选取2011年8月-2012年5月于我科使用氟维司群治疗的27例患者临床资料,观察其疾病进展时间、有效率、临床获益率及不良反应。结果中位疾病进展时间4.8个月,客观有效率(objective response rate,ORR)14.81%(4/27),临床获益率(CR+PR+SD>3个月)48.15%(13/27)。主要不良反应为乏力、食欲减退。结论氟维司群是他莫昔芬及芳香化酶抑制剂治疗失败后受体阳性晚期乳腺癌的有效药物,且耐受性好。Objective To observe the therapeutic effect and toxicity of fulvestrant on estrogen receptor（ER）-positive advanced breast cancer.Methods Twenty-seven patients who received fulvestrant treatment in our hospital from August 2011 to May 2012 were enrolled in this study.Their clinical data including the disease progression time,overall response rate,clinical beneficial rate,and side effects were analyzed.Results The median disease progression time,objective response rate,and 3-month clinical beneficial rate were 4.8 months,14.81%（4/27）,and 48.15%（13/27）,respectively.The main side effects were fatigue and anorexia.Conclusion Fulvestrant is a well-tolerated and effective drug for ER-positive advanced breast cancer when it fails to respond to tamoxifen and aromatase inhibitors.

关 键 词：氟维司群 受体阳性 转移性乳腺癌 内分泌治疗 

分 类 号：R737.9[医药卫生—肿瘤]